Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions

25 Jan 2024

Abstract excerpt

Brain tumors represent a heterogeneous group of neoplasms characterized by a high degree of aggressiveness and a poor prognosis. Despite recent therapeutic advances, the treatment of brain tumors, including glioblastoma (GBM), an aggressive primary brain tumor associated with poor prognosis and resistance to therapy, remains a significant challenge. Receptor tyrosine kinases (RTKs) are critical during development...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Glioma Diagnosis and Treatment
Share to Liver physiology and pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38334610
DOI: 10.3390/cells13030218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future DirectionsPMID 38334610Read ↗

HGF/MET Signaling in Malignant Brain TumorsSemantic proximity Read ↗

Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma MultiformeSemantic proximity Read ↗

MET Signaling Regulates Glioblastoma Stem CellsSemantic proximity Read ↗

Extensive MET alterations confer clinical response to MET inhibitors in gliomasSemantic proximity Read ↗

Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma.Semantic proximity Read ↗

Glioblastoma Multiforme Oncogenomics and Signaling PathwaysSemantic proximity Read ↗

EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.Semantic proximity Read ↗

Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.Semantic proximity Read ↗

Updated Insights on EGFR Signaling Pathways in GliomaSemantic proximity Read ↗

Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cellsSemantic proximity Read ↗

EGFR as a clinical marker in glioblastomas and other gliomas.Semantic proximity Read ↗

Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic TargetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.